Limb amputation has a severe somatic and psychological impact, that can furthermore have complications, which lead to increased morbidity, mortality, hospitalization days, health care costs, delay prosthetic application, and social reintegration. Proper therapeutic management must be initiated in cases with amputation stump complications to ensure the best result. This paper aims to present the therapeutic management of a patient with sepsis after above–the–knee amputation, performed after acute limb ischemia. The patient presented in our clinic 10 days postoperatively with local infection, wound dehiscence, and sepsis.

Intravascular papillary endothelial hyperplasia (IPEH), first described by Pierre Masson in 1923 is an uncommon benign vascular lesion that involves the skin or the soft tissue[1]. IPEH represents 2-4% of vascular tumors arising in the skin and soft tissue[2]. It usually occurs in the fourth decade of life and has a slight predilection for the female gender[3]. [...]

Over the last decade, chronic wounds such as venous or arterial ulcers, diabetic foot ulcers, pressure sores, and non-healing surgical wounds were brought into the spotlight of the medical community, due to their increasing prevalence and to their significant economic burden (1). In developed countries billions of dolars are spent each year (2,3) for the repeated hospitalizations and expensive treatment of patients suffering from non-healing ulcers. The persistent pain, either spontaneous or induced by treatment (4), the malodour of the ulceration (5), the mobility restrictions (6), and the excessive exudate, significantly impair the patients` quality of life, who might also experience secondary mood disorders (50-75%) (6) or sleep disorders (69%) (7).
The persistent bacterial colonization of the wound, as well as the longterm use of antibiotics predispose to the development of nosocomial infections with resistant strains such as methicillin resistant Staphylococcus aureus (MRSA), extended spectrum beta-lactamases (ESBLs) producing micro organisms, and multiple antibiotic resistant Pseudomonas aeruginosa(8).

Erythroderma is an uncommon potentially fatal skin disorder first described by Hebra in 1868. Erythroderma is a definitive term that refers to generalized erythema and desquamation affecting 90% of the body surface. It usually occurs in individuals older than 40, except when the subjacent disease is atopic dermatitis, seborrheic dermatitis or hereditary ichthyosis [1,2]. Erythroderma represents a reaction pattern, a maximal form of skin irritation that may be secondary to certain cutaneous diseases, drug reactions, infections, solid or hematological malignancies, and other conditions. In the absence of a suggestive history, the clinical and histopatho logic distinction between the underlying causes is often problematic and determining the specific etiology is very challenging, an important proportion of cases being classified as idiopathic erythroderma.

Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma is an extremely rare type of cytotoxic lymphoma reported for the first time by Berti et al. in 1999, (1) who described the tumor as a distinct clinico-pathologic entity with an aggressive clinical course. It presents as widespread, rapidly evolving papules, plaques, and tumors, often showing central necrosis and ulceration, histologically characterized by epidermotropism of CD8+ CD4- T cells. The condition has an increased tendency of spreading to extranodal sites, usually responds poorly to conventional therapies for classic CD4+ cutaneous T cell lymphomas (CTCLs), and has an unfavorable prognosis. (1-4)